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Prophylaxis Guidelines Ȃ A Plea to NICE 
 
Sir 
 
Dr. Alderson and Professor Baker wrote(1, 2) criticising our opinion piece(3) 
and preceding Lancet paper(4) concerning antibiotic prophylaxis (AP) for 
infective endocarditis (IE) but failed to disclose that they work for NICE and 
were involved in the recent review of guideline CG64. 
 
We remain concerned that the strict review criteria used by NICE exclude animal 
data and contemporary observational studies as providing sufficient evidence to 
influence guideline change. Despite our exhaustive efforts (and those of others), 
a definitive randomised controlled trial seems highly unlikely due to cost, 
complexity, and ethical issues.(5) As a consequence, the current criteria dictate 
that NICE guidance addressing this controversial question can never change.  In 
this context, the original 2008 decision to withdraw antibiotic prophylaxis (even 
for high-risk patients) in the absence of a randomised controlled trial (and when 
less observational evidence was available) seems questionable. 
 
Our observational study demonstrated cause for concern and there was a clinical 
and moral duty to report our findings.  In our manuscript, we highlighted the 
limitations of our data and explored alternative explanations for our findings.(4)  
 
Dr. Alderson and Professor Baker remarked that NICE had the Lancet data 
reviewed by an independent statistician who criticized our analysis, but failed to 
point out that he was commissioned by NICE to provide this critique or that the 
Lancet paper was reviewed by 9 independent experts (including 3 statisticians), 
none of whom raised similar criticisms. In fact, even the NICE statistician 
concluded that he could find ǲ
in the [Lancet] ǳǤ(6) However, by adding 2 extra change-points to the 
analysis (June 2004, June 2011), he could reduce the significance of the IE 
increase that we detected in March 2008. It should be highlighted that the aim of 
the study was to determine if the fall in AP prescribing caused by the March 
2008 NICE guidelines was associated with an increase in IE incidence and that 
was the change-point we therefore pre-specified. None of the Lancet reviewers 
questioned the use of this single change-point.  Furthermore, NICE gave no 
reason for choosing these extra two change-points. Nevertheless, adding extra 
change-points inevitably reduces the power to detect a significant change at any 
one of them.  
 
We acknowledge that NICE responded to a letter of concern we submitted during 
the public consultation process, but they have failed to address the important 
issues it raised. Our plea is that NICE engage in open discussion with 
cardiologists, dentists, researchers and patients with expertise on this topic.  
Currently, its interpretations remain at odds with pertinent stakeholders, 
including international guideline committees in Europe and the USA. 
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